{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T12:46:33Z","timestamp":1772801193639,"version":"3.50.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T00:00:00Z","timestamp":1660089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011102","name":"Seventh Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011272","name":"European Commission Seventh Framework Programme for Research and Technological Development Health","doi-asserted-by":"publisher","award":["278948"],"award-info":[{"award-number":["278948"]}],"id":[{"id":"10.13039\/100011272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["2014-003080-38"],"award-info":[{"award-number":["2014-003080-38"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials Communications"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.conctc.2022.100982","type":"journal-article","created":{"date-parts":[[2022,8,14]],"date-time":"2022-08-14T09:46:42Z","timestamp":1660470402000},"page":"100982","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Memantine as treatment for compulsivity in child and adolescent psychiatry: Descriptive findings from an incompleted randomized, double-blind, placebo-controlled trial"],"prefix":"10.1016","volume":"29","author":[{"given":"Larissa","family":"Niemeyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5322-7140","authenticated-orcid":false,"given":"Konstantin","family":"Mechler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf W.","family":"Dittmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4595-1144","authenticated-orcid":false,"given":"Tobias","family":"Banaschewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Buitelaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Durston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"H\u00e4ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.conctc.2022.100982_bib1","first-page":"1","article-title":"Frontostriatal functional connectivity correlates with repetitive behaviour across autism spectrum disorder and obsessive-compulsive disorder","author":"Akkermans","year":"2018","journal-title":"Psychol. Med."},{"issue":"11","key":"10.1016\/j.conctc.2022.100982_bib2","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1097\/00004583-199511000-00008","article-title":"Obsessive-compulsive disorder in a birth cohort of 18-year-olds: prevalence and predictors","volume":"34","author":"Douglass","year":"1995","journal-title":"J. Am. Acad. Child Adolesc. Psychiatr."},{"issue":"6","key":"10.1016\/j.conctc.2022.100982_bib3","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/00004583-198811000-00018","article-title":"Obsessive compulsive disorder in adolescence: an epidemiological study","volume":"27","author":"Flament","year":"1988","journal-title":"J. Am. Acad. Child Adolesc. Psychiatr."},{"issue":"11","key":"10.1016\/j.conctc.2022.100982_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141703","article-title":"Obsessive-compulsive disorder and autism spectrum disorders: longitudinal and offspring risk","volume":"10","author":"Meier","year":"2015","journal-title":"PLoS One"},{"issue":"7413","key":"10.1016\/j.conctc.2022.100982_bib5","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/bmj.327.7413.488","article-title":"Diagnosis of autism","volume":"327","author":"Baird","year":"2003","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.conctc.2022.100982_bib6","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.1469-7610.2011.02395.x","article-title":"A randomized controlled trial of Hanen's 'More than Words' in toddlers with early autism symptoms","volume":"52","author":"Carter","year":"2011","journal-title":"J. Child Psychol. Psychiatry Allied Discip."},{"issue":"8","key":"10.1016\/j.conctc.2022.100982_bib7","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.cpr.2013.07.005","article-title":"The TEACCH program for children and adults with autism: a meta-analysis of intervention studies","volume":"33","author":"Virues-Ortega","year":"2013","journal-title":"Clin. Psychol. Rev."},{"key":"10.1016\/j.conctc.2022.100982_bib8","article-title":"Autism","author":"Parr","year":"2010","journal-title":"Clin. Evid."},{"issue":"5","key":"10.1016\/j.conctc.2022.100982_bib9","doi-asserted-by":"crossref","first-page":"e1124","DOI":"10.1038\/tp.2017.101","article-title":"Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders","volume":"7","author":"Lemonnier","year":"2017","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.conctc.2022.100982_bib10","doi-asserted-by":"crossref","DOI":"10.1007\/s40272-019-00333-x","article-title":"Safety and tolerability of antipsychotic medication in individuals with autism spectrum disorder: a systematic review and meta-analysis","author":"Alfageh","year":"2019","journal-title":"Paediatric drugs"},{"key":"10.1016\/j.conctc.2022.100982_bib11","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.psychres.2019.04.013","article-title":"Prevalence and predictors of psychotropic medication use in adolescents and adults with autism spectrum disorder in Italy: a cross-sectional study","volume":"276","author":"Fusar-Poli","year":"2019","journal-title":"Psychiatr. Res."},{"issue":"4","key":"10.1016\/j.conctc.2022.100982_bib12","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/aur.2059","article-title":"Atomoxetine for attention deficit hyperactivity disorder in children and adolescents with autism: a systematic review and meta-analysis","volume":"12","author":"Patra","year":"2019","journal-title":"Autism Res. : Off. J. Int. Soc. Autism Res."},{"issue":"6","key":"10.1016\/j.conctc.2022.100982_bib13","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2165\/00023210-200923060-00005","article-title":"Aripiprazole monotherapy in children and young adolescents with pervasive developmental disorders: a retrospective study","volume":"23","author":"Masi","year":"2009","journal-title":"CNS Drugs"},{"issue":"9","key":"10.1016\/j.conctc.2022.100982_bib14","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1089\/cap.2014.0055","article-title":"Lack of effect of risperidone on core autistic symptoms: data from a longitudinal study","volume":"24","author":"Marrus","year":"2014","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.conctc.2022.100982_bib15","series-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-5\u00ae)","year":"2013"},{"issue":"5","key":"10.1016\/j.conctc.2022.100982_bib16","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/archdischild-2014-306934","article-title":"Obsessive-compulsive disorder in children and adolescents","volume":"100","author":"Krebs","year":"2015","journal-title":"Arch. Dis. Child."},{"issue":"Suppl 1","key":"10.1016\/j.conctc.2022.100982_bib17","first-page":"S119","article-title":"Challenges in the diagnosis and treatment of pediatric obsessive-compulsive disorder","volume":"61","author":"Westwell-Roper","year":"2019","journal-title":"Indian J. Psychiatr."},{"issue":"4","key":"10.1016\/j.conctc.2022.100982_bib18","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1089\/cap.2010.0040","article-title":"Treatment of pediatric obsessive-compulsive disorder: a review","volume":"20","author":"Mancuso","year":"2010","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.conctc.2022.100982_bib19","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1212\/01.CON.0000466666.12779.07","article-title":"Obsessive-compulsive disorder","volume":"21","author":"Drubach","year":"2015","journal-title":"Continuum"},{"issue":"3","key":"10.1016\/j.conctc.2022.100982_bib20","first-page":"257","article-title":"Obsessive-compulsive disorder","volume":"37","author":"Goodman","year":"2014","journal-title":"Psychiatr. Clin."},{"issue":"7","key":"10.1016\/j.conctc.2022.100982_bib21","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1176\/ajp.2006.163.7.1282","article-title":"Motor inhibition and cognitive flexibility in obsessive-compulsive disorder and trichotillomania","volume":"163","author":"Chamberlain","year":"2006","journal-title":"Am. J. Psychiatr."},{"issue":"1","key":"10.1016\/j.conctc.2022.100982_bib22","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.tics.2011.11.009","article-title":"Neurocognitive endophenotypes of impulsivity and compulsivity: towards dimensional psychiatry","volume":"16","author":"Robbins","year":"2012","journal-title":"Trends Cognit. Sci."},{"key":"10.1016\/j.conctc.2022.100982_bib23","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.neubiorev.2015.02.009","article-title":"Fronto-striatal glutamatergic compounds in compulsive and impulsive syndromes: a review of magnetic resonance spectroscopy studies","volume":"52","author":"Naaijen","year":"2015","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"9","key":"10.1016\/j.conctc.2022.100982_bib24","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1097\/00004583-200009000-00008","article-title":"Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine","volume":"39","author":"Rosenberg","year":"2000","journal-title":"J. Am. Acad. Child Adolesc. Psychiatr."},{"key":"10.1016\/j.conctc.2022.100982_bib25","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1038\/npp.2016.260","article-title":"Fronto-Striatal glutamate in autism spectrum disorder and obsessive compulsive disorder","volume":"42","author":"Naaijen","year":"2017","journal-title":"Neuropsychopharmacology : Off. Publ. Am. College Neuropsychopharmacol."},{"issue":"6","key":"10.1016\/j.conctc.2022.100982_bib26","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.neuropharm.2007.07.013","article-title":"Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse","volume":"53","author":"Parsons","year":"2007","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.conctc.2022.100982_bib27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.coph.2005.09.007","article-title":"Mechanism of action of memantine","volume":"6","author":"Johnson","year":"2006","journal-title":"Curr. Opin. Pharmacol."},{"issue":"4","key":"10.1016\/j.conctc.2022.100982_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0123289","article-title":"Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis","volume":"10","author":"Matsunaga","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.conctc.2022.100982_bib29","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1024\/1422-4917\/a000546","article-title":"Glutamatergic agents in the treatment of compulsivity and impulsivity in child and adolescent psychiatry: a systematic review of the literature","volume":"46","author":"Mechler","year":"2018","journal-title":"Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie"},{"key":"10.1016\/j.conctc.2022.100982_bib30","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3389\/fped.2014.00087","article-title":"The use of medications approved for Alzheimer's disease in autism spectrum disorder: a systematic review","volume":"2","author":"Rossignol","year":"2014","journal-title":"Frontiers in pediatrics"},{"issue":"2","key":"10.1016\/j.conctc.2022.100982_bib31","first-page":"166","article-title":"Memantine: a review of possible uses in child and adolescent psychiatry","volume":"22","author":"Hosenbocus","year":"2013","journal-title":"Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent"},{"key":"10.1016\/j.conctc.2022.100982_bib32","doi-asserted-by":"crossref","DOI":"10.1177\/1362361318824103","article-title":"Efficacy and safety of memantine in children with autism spectrum disorder: results from three phase 2 multicenter studies","author":"Hardan","year":"2019","journal-title":"Autism : Int. J. Res. Pract."},{"issue":"2","key":"10.1016\/j.conctc.2022.100982_bib33","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1176\/appi.ajp.2008.08091427","article-title":"Memantine as an augmenting agent for severe pediatric OCD","volume":"166","author":"Hezel","year":"2009","journal-title":"Am. J. Psychiatr."},{"issue":"3","key":"10.1016\/j.conctc.2022.100982_bib34","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1177\/104012371803000307","article-title":"The use of memantine in neuropsychiatric disorders: an overview","volume":"30","author":"Lu","year":"2018","journal-title":"Ann. Clin. Psychiatr. : Off. J. Am. Acad. Clin. Psychiatr."},{"issue":"6","key":"10.1016\/j.conctc.2022.100982_bib35","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1055\/s-0043-120268","article-title":"Memantine augmentation improves symptoms in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a randomized controlled trial","volume":"51","author":"Modarresi","year":"2018","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"10.1016\/j.conctc.2022.100982_bib36","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13063-016-1266-8","article-title":"Glutamatergic medication in the treatment of obsessive compulsive disorder (OCD) and autism spectrum disorder (ASD) - study protocol for a randomised controlled trial","volume":"17","author":"H\u00e4ge","year":"2016","journal-title":"Trials"},{"issue":"6","key":"10.1016\/j.conctc.2022.100982_bib37","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/00004583-199706000-00023","article-title":"Children's Yale-Brown obsessive compulsive scale: reliability and validity","volume":"36","author":"Scahill","year":"1997","journal-title":"J. Am. Acad. Child Adolesc. Psychiatr."},{"key":"10.1016\/j.conctc.2022.100982_bib38","first-page":"839","article-title":"Special feature: rating scales and assessment instruments for use in pediatric psychopharmacology research","volume":"21","year":"1985","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.conctc.2022.100982_bib39","series-title":"ECDEU Assessment Manual for Psychopharmacology","first-page":"534","author":"Guy","year":"1976"},{"issue":"11","key":"10.1016\/j.conctc.2022.100982_bib40","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1001\/archpsyc.1983.01790100074010","article-title":"A children's global assessment scale (CGAS)","volume":"40","author":"Shaffer","year":"1983","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.conctc.2022.100982_bib41","series-title":"Proceedings of the 54th Annual Meeting of the American Academy of Child and Adolescent Psychiatry","article-title":"The pediatric adverse event rating scale","author":"March","year":"2007"},{"issue":"7","key":"10.1016\/j.conctc.2022.100982_bib42","doi-asserted-by":"crossref","first-page":"977","DOI":"10.2174\/1570159X15666170320104237","article-title":"Glutamate-modulating drugs as a potential therapeutic strategy in obsessive-compulsive disorder","volume":"15","author":"Marinova","year":"2017","journal-title":"Curr. Neuropharmacol."},{"issue":"1","key":"10.1016\/j.conctc.2022.100982_bib43","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/JCP.0b013e3181c856de","article-title":"A single-blinded case-control study of memantine in severe obsessive-compulsive disorder","volume":"30","author":"Stewart","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.conctc.2022.100982_bib44","first-page":"19","article-title":"Comparing efficacy and side effects of memantine vs. Risperidone in the treatment of autistic disorder","volume":"50","author":"Nikvarz","year":"2017","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"10.1016\/j.conctc.2022.100982_bib45","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00213-006-0518-9","article-title":"A retrospective study of memantine in children and adolescents with pervasive developmental disorders","volume":"191","author":"Erickson","year":"2007","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.conctc.2022.100982_bib46","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s40266-015-0266-9","article-title":"A risk-benefit assessment of dementia medications: systematic review of the evidence","volume":"32","author":"Buckley","year":"2015","journal-title":"Drugs Aging"},{"issue":"5","key":"10.1016\/j.conctc.2022.100982_bib47","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1089\/cap.2015.0146","article-title":"Safety and efficacy of memantine in children with autism: randomized, placebo-controlled study and open-label extension","volume":"27","author":"Aman","year":"2017","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"12","key":"10.1016\/j.conctc.2022.100982_bib48","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1007\/s10803-009-0807-3","article-title":"Open-label memantine in fragile X syndrome","volume":"39","author":"Erickson","year":"2009","journal-title":"J. Autism Dev. Disord."},{"issue":"1","key":"10.1016\/j.conctc.2022.100982_bib49","first-page":"23","article-title":"High rate of non-eligibility: methodological factors impacting on recruitment for a multicentre, double-blind study of paediatric patients with major depressive disorder","volume":"46","author":"Bliznak","year":"2013","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"10.1016\/j.conctc.2022.100982_bib50","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13063-021-05119-6","article-title":"Include me if you can\"-reasons for low enrollment of pediatric patients in a psychopharmacological trial","volume":"22","author":"Niemeyer","year":"2021","journal-title":"Trials"},{"issue":"6","key":"10.1016\/j.conctc.2022.100982_bib51","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1024\/1422-4917\/a000690","volume":"47","author":"Dittmann","year":"2019","journal-title":"Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie"}],"container-title":["Contemporary Clinical Trials Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865422000990?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865422000990?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:07:05Z","timestamp":1762520825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451865422000990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":51,"alternative-id":["S2451865422000990"],"URL":"https:\/\/doi.org\/10.1016\/j.conctc.2022.100982","relation":{},"ISSN":["2451-8654"],"issn-type":[{"value":"2451-8654","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Memantine as treatment for compulsivity in child and adolescent psychiatry: Descriptive findings from an incompleted randomized, double-blind, placebo-controlled trial","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.conctc.2022.100982","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100982"}}